UDENYCA
Peakpegfilgrastim-cbqv
BLAINJECTIONINJECTABLE
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UDENYCA (pegfilgrastim-cbqv) is an injectable leukocyte growth factor administered via injection for systemic use. It is a granulocyte colony-stimulating factor (G-CSF) analog indicated for reducing the duration of severe neutropenia and associated complications in patients receiving myelosuppressive anticancer chemotherapy. The drug works by stimulating the proliferation and differentiation of neutrophil progenitor cells, thereby enhancing immune function during chemotherapy-induced neutropenia. UDENYCA represents a pegylated, long-acting formulation of filgrastim, positioning it as a supportive care agent in oncology practice.
$0.0BPart D
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
Started Aug 2020
200 enrolled
Febrile NeutropeniaNon-myeloid Malignancy
Career Relevance
UDENYCA creates opportunities for oncology-focused brand managers, medical science liaisons, hospital account managers, and specialty pharmacy representatives who engage with oncology practice. Success in this role requires expertise in supportive care oncology, understanding of chemotherapy-induced neutropenia management, familiarity with formulary access strategies, and strong relationships with hospital pharmacy and oncology departments. Currently, zero open positions are linked to UDENYCA in available job tracking data.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.